What is B. Riley's Estimate for CAPR Q2 Earnings?

Key Points

• B. Riley has set a **Q2 2026 EPS estimate** for Capricor Therapeutics at **($0.42)**, maintaining a **"Strong-Buy" rating** on the stock.
• Capricor Therapeutics reported **($0.57) EPS** for its last quarter, missing expectations by **($0.09)**, and has a **negative return on equity** of **62.71%**.
• The stock has seen **institutional interest** with Tower Research increasing its stake by **280.8%**, while **21.68%** of shares are currently held by institutional investors and hedge funds.

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) - Research analysts at B. Riley issued their Q2 2026 EPS estimates for shares of Capricor Therapeutics in a report released on Sunday, September 14th. B. Riley analyst M. El-Saadi forecasts that the biotechnology company will post earnings per share of ($0.42) for the quarter. B. Riley currently has a "Strong-Buy" rating on the stock. The consensus estimate for Capricor Therapeutics' current full-year earnings is ($1.21) per share. B. Riley also issued estimates for Capricor Therapeutics' Q3 2026 earnings at ($0.39) EPS and Q4 2026 earnings at $2.34 EPS.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last released its quarterly earnings data on Monday, August 11th. The biotechnology company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.09). Capricor Therapeutics had a negative return on equity of 62.71% and a negative net margin of 181.71%.

CAPR has been the topic of a number of other research reports. Alliance Global Partners reaffirmed a "buy" rating on shares of Capricor Therapeutics in a research note on Monday, July 14th. HC Wainwright reaffirmed a "buy" rating and issued a $24.00 price target on shares of Capricor Therapeutics in a research note on Thursday, September 11th. Wall Street Zen lowered shares of Capricor Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Roth Capital lowered their price objective on shares of Capricor Therapeutics from $31.00 to $12.00 and set a "buy" rating on the stock in a report on Monday, July 14th. Finally, Jones Trading lowered their price objective on shares of Capricor Therapeutics from $40.00 to $29.00 and set a "buy" rating on the stock in a report on Wednesday, June 25th. One analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company. According to MarketBeat, Capricor Therapeutics currently has a consensus rating of "Buy" and an average target price of $22.56.

Capricor Therapeutics Price Performance

Capricor Therapeutics stock opened at $6.04 on Tuesday. The company's 50 day simple moving average is $7.31 and its 200 day simple moving average is $9.71. Capricor Therapeutics has a fifty-two week low of $4.35 and a fifty-two week high of $23.40. The firm has a market capitalization of $276.15 million, a price-to-earnings ratio of -3.68 and a beta of 0.73.

Hedge Funds Weigh In On Capricor Therapeutics

A number of institutional investors have recently added to or reduced their stakes in CAPR. Tower Research Capital LLC TRC increased its holdings in Capricor Therapeutics by 280.8% during the second quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company's stock worth $67,000 after buying an additional 4,976 shares during the last quarter. Citizens Financial Group Inc. RI acquired a new position in Capricor Therapeutics during the first quarter worth $95,000. KLP Kapitalforvaltning AS increased its holdings in Capricor Therapeutics by 65.2% during the second quarter. KLP Kapitalforvaltning AS now owns 10,900 shares of the biotechnology company's stock worth $108,000 after buying an additional 4,300 shares during the last quarter. Arizona State Retirement System acquired a new position in Capricor Therapeutics during the first quarter worth $111,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Capricor Therapeutics by 31.4% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,246 shares of the biotechnology company's stock worth $126,000 after buying an additional 3,162 shares during the last quarter. 21.68% of the stock is currently owned by institutional investors and hedge funds.

About Capricor Therapeutics

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.